Argentine hemorrhagic fever

Argentine hemorrhagic fever
SpecialtyInfectious disease

Argentine hemorrhagic fever (AHF) or O'Higgins disease, also known in Argentina as mal de los rastrojos (stubble disease) is a hemorrhagic fever and zoonotic infectious disease occurring in Argentina. It is caused by the Junín virus[1] (an arenavirus, closely related to the Machupo virus, causative agent of Bolivian hemorrhagic fever). Its reservoir of infection is the drylands vesper mouse, a rodent found in Argentina and Paraguay.

Signs and symptoms

AHF is a grave acute disease which may progress to recovery or death in 1 to 2 weeks. The incubation time of the disease is between 10 and 12 days, after which the first symptoms appear: fever, headaches, weakness, loss of appetite and will. These intensify less than a week later, forcing the infected to lie down, and producing stronger symptoms such as vascular, renal, hematological and neurological alterations. This stage lasts about 3 weeks.

Cause

Junin virus

In terms of the etiology we find that Argentine hemorrhagic disease is caused by the Junin virus (JUNV)[2]

Diagnosis

The evaluation for this hemorrhagic fever can be done via:[3]

Prevention

The Candid #1 vaccine for AHF was created in 1985 by Argentine virologist Dr. Julio Barrera Oro. The vaccine was manufactured by the Salk Institute in the United States, and became available in Argentina in 1990. Antibodies produced by Candid #1 vaccination have also demonstrated cross-reactivity with Machupo virus in Rhesus macaques, and thus Candid #1 been considered for prophylactic use against Bolivian hemorrhagic fever.[4]

Candid #1 has been applied to adult high-risk population and is 95.5% effective.[5] Between 1991 and 2005 more than 240,000 people were vaccinated, achieving a great decrease in the numbers of reported cases (94 suspect and 19 confirmed in 2005).

On 29 August 2006 the Maiztegui Institute obtained certification for the production of the vaccine in Argentina. The vaccine produced in Argentina was found to be of similar effectiveness to the US vaccine.[6] Details of the vaccine were published in 2011,[5] and a protocol for production of the vaccine was published in 2018.[7] Demand for the vaccine is insufficient to be commercially appealing due to the small target population, and it is considered an orphan drug; the Argentine government committed itself to manufacture and sponsor Candid #1 vaccine.[5]

Treatment

Ribavirin also has shown some promise in treating arenaviral diseases.

If untreated, the mortality of AHF reaches 15–30%. The specific treatment includes plasma of recovered patients, which, if started early, is extremely effective and reduces mortality to 1%.[8]

Epidemiology

The disease was first reported in the town of O'Higgins in Buenos Aires province, Argentina in 1958, giving it one of the names by which it is known.[9] Theories about its nature included: Weil's disease, leptospirosis, chemical pollution.[9] It was associated with fields containing stubble after the harvest, giving it another of its names.

The endemic area of AHF covers approximately 150,000 km2, compromising the provinces of Buenos Aires, Córdoba, Santa Fe and La Pampa, with an estimated risk population of 5 million.

The natural reservoir of infection, a small rodent known locally as ratón maicero ("maize mouse"; Calomys musculinus), has chronic asymptomatic infection, and spreads the virus through its saliva and urine. Infection is produced through contact of skin or mucous membranes, or through inhalation of infected particles. It is found mostly in people who reside or work in rural areas; 80% of those infected are males between 15 and 60 years of age.

History

The disease was first detected in the 1950s in the Junín Partido in Buenos Aires, after which its agent, the Junín virus, was named upon its identification in 1958. In the early years, about 1,000 cases per year were recorded, with a high mortality rate (more than 30%). The initial introduction of treatment serums in the 1970s reduced this lethality.

Society and culture

Weaponization

Argentine hemorrhagic fever was one of three hemorrhagic fevers and one of more than a dozen agents that the United States researched as potential biological weapons before the nation suspended its biological weapons program.[10] The Soviet Union also conducted research and developing programs on the potential of the hemorragic fever as a biological weapon.[11]

References

  1. ↑ Grant A, Seregin A, Huang C, Kolokoltsova O, Brasier A, Peters C, Paessler S (October 2012). "Junín virus pathogenesis and virus replication". Viruses. National Institutes of Health. 4 (10): 2317–2339. doi:10.3390/v4102317. PMC 3497054. PMID 23202466. Junín virus, the etiological agent of Argentine hemorrhagic fever, causes significant morbidity and mortality.
  2. ↑ "Argentine hemorrhagic fever (Concept Id: C0019097) - MedGen - NCBI". www.ncbi.nlm.nih.gov. Archived from the original on 2 February 2023. Retrieved 18 April 2023.
  3. ↑ "South American haemorrhagic fevers - Symptoms, diagnosis and treatment | BMJ Best Practice". bestpractice.bmj.com. Archived from the original on 22 February 2023. Retrieved 18 April 2023.
  4. ↑ McLay L, Liang Y, Ly H (January 2014). "Comparative analysis of disease pathogenesis and molecular mechanisms of New World and Old World arenavirus infections". The Journal of General Virology. 95 (Pt 1): 1–15. doi:10.1099/vir.0.057000-0. PMC 4093776. PMID 24068704.
  5. 1 2 3 Ambrosio A, Saavedra M, Mariani M, Gamboa G, Maiza A (June 2011). "Argentine hemorrhagic fever vaccines". Human Vaccines. 7 (6): 694–700. doi:10.4161/hv.7.6.15198. PMID 21451263. S2CID 42889001.
  6. ↑ Enria DA, Ambrosio AM, Briggiler AM, Feuillade MR, Crivelli E (2010). "Vacuna contra la fiebre hemorrágica argentina Candid#1 producida en la Argentina. Inmunogenicidad y seguridad" [Candid#1 vaccine against Argentine hemorrhagic fever produced in Argentina. Immunogenicity and safety]. MEDICINA (Buenos Aires). 70: 215–222. Archived from the original on 2021-01-18. Retrieved 2023-04-11. Article in Spanish with abstract in English.
  7. ↑ Ambrosio AM, Mariani MA, Maiza AS, Gamboa GS, Fossa SE, Bottale AJ (2018). "Protocol for the Production of a Vaccine Against Argentinian Hemorrhagic Fever". Hemorrhagic Fever Viruses. Methods in Molecular Biology. Vol. 1604. pp. 305–329. doi:10.1007/978-1-4939-6981-4_24. ISBN 978-1-4939-6980-7. PMID 28986845.
  8. ↑ van Griensven J, De Weiggheleire A, Delamou A, Smith PG, Edwards T, Vandekerckhove P, et al. (January 2016). "The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field". Clinical Infectious Diseases. 62 (1): 69–74. doi:10.1093/cid/civ680. PMC 4678103. PMID 26261205.
  9. 1 2 Agnese G (July 2007). "Una rara enfermedad alarma a la modesta población de O'Higgins. Análisis del discurso de la prensa escrita sobre la epidemia de Fiebre Hemorrágica Argentina de 1958" [A rare disease alarms the modest population of O'Higgins. Analysis of the discourse of the written press on the Argentine Hemorrhagic Fever epidemic of 1958] (PDF). Revista de Historia & Humanidades Médicas [Journal of Medical History and Humanities] (in Spanish). 3 (1). Archived from the original (PDF) on 12 January 2014.{{cite journal}}: CS1 maint: unrecognized language (link)
  10. ↑ ""Chemical and Biological Weapons: Possession and Programs Past and Present". James Martin Center for Nonproliferation Studies. Middlebury College. 9 April 2002. Archived from the original on 2 October 2001. Retrieved 14 November 2008.
  11. ↑ Wheelis M, Rózsa L, Dando M (2006). Deadly cultures: biological weapons since 1945. Cambridge, Mass.: Harvard University Press. p. 141. ISBN 0-674-01699-8.

Further reading

Classification
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.